期刊
JOURNAL OF CROHNS & COLITIS
卷 16, 期 1, 页码 162-165出版社
OXFORD UNIV PRESS
DOI: 10.1093/ecco-jcc/jjab118
关键词
Inflammatory bowel diseases; Crohn's disease; ulcerative colitis; biomarker; prognostic predictive
资金
- Medical Research Council [MRC] New Investigator Research Grant [MR/T001917/1]
- MRC [MR/T001917/1] Funding Source: UKRI
Inflammatory bowel diseases like Crohn's disease and ulcerative colitis are complex conditions that require personalized treatment approaches. Developing biomarkers to predict disease course and treatment response is challenging.
Inflammatory bowel diseases [IBD] such as Crohn's disease [CD] and ulcerative colitis [UC] are complex conditions presenting with a wide range of phenotypes. Given major variation in disease severity and outcomes as well as response to existing therapies, a personalised treatment approach stands the chance of improving the overall disease outcome as well as minimising potentially harmful side effects. However, disease activity or distribution at the point of diagnosis are poor predictors of future disease outcome. Hence, the urgent need to develop biomarkers that could either predict the overall disease course [i.e., disease prognostic biomarkers] or the response to individual therapies [i.e., disease predictive biomarkers]. Despite the widely accepted need for such biomarkers to improve the management of IBD patients, their development has proven to be challenging for a number of reasons. Based on our own experience in this field, we perform a reality check on existing evidence, discuss main challenges, and outline future perspectives.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据